The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury.In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine bromphenirami...

The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 36-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride 28-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate tilorone analogue R-9536-DA indoprofen ciclopiroxolamine tryptophan ansindione nabumetone oxybendazole albendazole tropicamide pramoxine hydrochloride atenolol mebendazole carbetapentane citrate monens...

The present invention relates to methods for enhancing Hypoxia inducible factor- 1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 36-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride 28-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate tilorone analogue R-9536-DA indoprofen ciclopiroxolamine tryptophan ansindione nabumetone oxybendazole albendazole tropicamide pramoxine hydrochloride atenolol mebendazole carbetapentane citrate monen...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury.In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine bromphenirami...

PROBLEM TO BE SOLVED: To obtain the subject promoter capable of recovering a reduced skin barrier function in an extremely short time capable of preventing epidermal growth disorder etc. caused by reduction in the epidermal function of skin by including cetraxate hydrochloride.SOLUTION: This promoter contains (A) cetraxale hydrochloride. The promoter for recovering the barrier function of skin contains (B) at least one histamine H1 antagonist. Further the promoter for recovering the barrier func...